BrainStorm Cell Therapeutics has received a recommendation from the independent Data Safety Monitoring Board (DSMB) to continue the Phase II clinical trial of NurOwn in progressive multiple sclerosis patients.

The recommendation comes after the review of safety outcomes from a pre-specified interim analysis involving nine study participants. DSMB said that the trial can continue without any changes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

NurOwn, which is made up of mesenchymal stromal stem cells secreting neurotrophic factors (MSC-NTF) cells, is designed to target disease pathways in neurodegenerative disorders.

MSC-NTF cells are generated using autologous, mesenchymal stem cells (MSCs) that have been extracted from bone marrow, expanded and differentiated ex-vivo.

BrainStorm said that autologous MSC-NTF cells can deliver various NTFs and immunomodulatory cytokines directly to the target site and induce a biological effect to slow or stabilise disease progression.

The multi-centre, open-label, multi-dose Phase II trial is assessing the safety and efficacy of repeated intrathecal administration of NurOwn in a total of 20 patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary outcome of the study is the incidence of treatment-emergent adverse events, while secondary outcome measures include the change in timed 25-foot walking speed or 9-Hole Peg Test from baseline and number of patients with changes in neurotrophic factors.

BrainStorm Cell Therapeutics president and CEO Chaim Lebovits said: “BrainStorm is focused on completing the NurOwn progressive MS Phase II study and to bringing a much-needed treatment option to MS patients.

“The DSMB review confirms the safety profile at this stage of the study of repeat dose intrathecal administration of NurOwn in this patient population.”

In addition to the Phase II progressive multiple sclerosis trial, the company is assessing NurOwn in a randomised, placebo-controlled Phase III trial to treat amyotrophic lateral sclerosis (ALS).